Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
Our focus is on improving the lives of patients who have no approved therapies for their diseases. Everyone in our company shares the same goal: delivering safe and effective therapies as quickly as possible to the people who need them.
Visit our community guidelines at: ultragenyx.co/community